{"public_id":"cl_8a778e2ac9b78feeeb5fccfac255654b","status":"active","superseded_by_public_id":null,"corpus_id":7120096,"text":"Dose-limiting toxicity was haematologic, specifically grade 4 thrombocytopenia, at dose level 2.","confidence":0.98,"paper":{"corpus_id":7120096,"title":"A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer","url":"https://sah.borca.ai/papers/7120096"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.98,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_969a6b1d697c5b1441003360db8be02b","name":"grade 4 thrombocytopenia","description":"A severe reduction in platelet count classified as grade 4 toxicity.","types":["adverse event"],"url":"https://sah.borca.ai/concepts/co_969a6b1d697c5b1441003360db8be02b"},{"public_id":"co_a4189d35236767505a49f4d11f479a0b","name":"dose-limiting toxicity","description":"An adverse effect that restricts dose escalation in a clinical trial.","types":["safety outcome"],"url":"https://sah.borca.ai/concepts/co_a4189d35236767505a49f4d11f479a0b"},{"public_id":"co_ced735f577ca74a945e104cb458b8761","name":"dose level 2","description":"The second planned dose-escalation level tested in the trial.","types":["trial dose level"],"url":"https://sah.borca.ai/concepts/co_ced735f577ca74a945e104cb458b8761"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_8a778e2ac9b78feeeb5fccfac255654b"}